Karyopharm Therapeutics (KPTI) Return on Sales (2016 - 2025)
Historic Return on Sales for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 3.0%.
- Karyopharm Therapeutics' Return on Sales fell 19900.0% to 3.0% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.34%, marking a year-over-year decrease of 8200.0%. This contributed to the annual value of 1.34% for FY2025, which is 8200.0% down from last year.
- Latest data reveals that Karyopharm Therapeutics reported Return on Sales of 3.0% as of Q4 2025, which was down 19900.0% from 0.75% recorded in Q3 2025.
- Karyopharm Therapeutics' Return on Sales' 5-year high stood at 0.56% during Q2 2024, with a 5-year trough of 3.0% in Q4 2025.
- Its 5-year average for Return on Sales is 1.1%, with a median of 0.99% in 2022.
- As far as peak fluctuations go, Karyopharm Therapeutics' Return on Sales soared by 16000bps in 2022, and later crashed by -19900bps in 2025.
- Karyopharm Therapeutics' Return on Sales (Quarter) stood at 0.31% in 2021, then tumbled by -483bps to 1.17% in 2022, then dropped by -6bps to 1.25% in 2023, then increased by 19bps to 1.01% in 2024, then tumbled by -197bps to 3.0% in 2025.
- Its Return on Sales was 3.0% in Q4 2025, compared to 0.75% in Q3 2025 and 0.98% in Q2 2025.